Whole exome sequencing identifies MAP3K1, MSH2, and MLH1 as potential cancer-predisposing genes in familialearly-onset colorectal cancer
Abstract The incidence of early-onset colorectal cancer (CRC), which affects people under50, is increasing…
Royan TuCAGene at a Glance
Royan TuCAGene Knowledge-Based Company is a pioneering organization in the fields of genetics and biotechnology, founded in 2015 with the mission of developing innovative therapies based on genomic science. The company’s experts focus on integrating cutting-edge genetic technologies, immunovirotherapy, and bioinformatics to advance personalized and next-generation treatments aimed at combating therapy-resistant cancers. On the path toward transforming modern medicine, we concentrate on targeted therapies driven by precise biological data analysis, with the belief that every individual’s genetic code is the key to their effective treatment.
ImmunoVirotherapy:
A Novel Perspective in Oncology
Immunotherapy is one of the advanced approaches in cancer treatment which, unlike traditional therapies, not only focuses on the physical elimination of tumors but also activates the body’s natural ability to defend against cancer. This can result in durable and long-term therapeutic responses. ImmunoVirotherapy represents a cutting-edge branch of cancer therapy that integrates two principal therapeutic mechanisms: activation of the immune system and the use of genetically engineered viruses to directly target and eliminate cancer cells. In this approach, oncolytic viruses serve as dual-purpose agents; on the one hand, they replicate within tumor cells leading to their destruction, and on the other hand, they enhance the anti-tumor immune response within the body.
Specialized Department of Bioinformatics
We believe that each individual’s genome represents a unique and precise blueprint for their health, disease prevention, and treatment. The Bioinformatics Division of Royan TuCAGene, supported by the scientific expertise of its research team, provides advanced analytical services in the fields of genomic and transcriptomic data. The team consists of specialists and researchers with distinguished academic backgrounds and extensive experience in international collaborations. By leveraging the latest scientific achievements and computational technologies, they deliver accurate, reliable services that adhere to global standards.
Research and Development Division
As a technology-driven company specializing in virus engineering, vectors, and the development of novel cancer therapies, we conduct extensive and targeted research and development activities, supported by a team of experts and state-of-the-art laboratory infrastructure. Adherence to international GLP standards in research and GMP conditions in production enables us to manage and execute biological and bioinformatics projects from the design stage through to the final product.
Design and construction of innovative vectors
Conducting cellular assays and preclinical animal studies
Production of biological products under GMP conditions
Documentation and Preparation of CTD Dossiers Approved by the Iran Food and Drug Administration (IFDA)
Our Supporters and Collaborators
Professional & Business Services
The Commercial Division of Royan TuCAGene, with a focus on quality, rapid supply, and after-sales services, strives to meet the specialized needs of the country’s scientific and industrial community in accordance with the highest international standards. Our goal is to create an effective bridge connecting universities and researchers, research centers, pharmaceutical industries, and diagnostic and genetic laboratories with the most reputable international manufacturers.
Premium Genetic & Biotech Lab Supplies from Trusted International Brands
Providing Advanced Equipment, Including Next-Generation DNA Sequencers
Contract Research Services: Sequencing, Genetic Analysis & Scientific Consulting
ocumentation and Preparation of CTD Dossiers Approved by the Iranian Food and Drug Administration (IFDA)
Latest News and Articles
Genomic alterations and possible druggable mutations in carcinoma of unknown primary (CUP)
Introduction: Carcinoma of Unknown Primary (CUP) is a heterogeneous and metastatic disease where the…
Cancer/testis antigens FBXO39 and CEP55 expression correlates with survival in GBM patients
Abstract Background Glioblastoma multiform (GBM) is a primary brain malignancy resistant to conventional therapies,…
Have an innovative idea?
We reach out to researchers and innovators in knowledge-based companies, fostering collaboration and driving the future of science together.